It has been known for 100 years that the brain is protected by thousands of tight capillaries that form a barrier—a defence mechanism but also an obstacle to the use of promising drugs to treat diseases affecting the central nervous system.
Ernest Giralt: “This barrier is responsible for the low success rate of new drugs to enter the brain. We now have the strategies to overcome it.”
20 pioneering scientists present their latest research on the barrier and the breakthroughs in therapeutic shuttle transporters that target the brain in the Blood-Brain-Barrier Conference, an event organised by IRB Barcelona and supported by the BBVA Foundation.
One of the latest results is a shuttle based on bee venom developed at IRB Barcelona.
The medical newspaper Diario Médico has echoed on the research performed by Natàlia Carulla's group that has recently been published in Scientific Reports, a journal that belongs to the Nature group. The study offers data that challenge current views about the number and the shape of the first aggregates formed by amyloid beta protein, a molecule related to Alzheimer's...
Natàlia Carulla’s research group provides information that questions the widely accepted premise regarding the number of molecules and the shape of the first aggregates formed by amyloid beta protein
Amyloid beta protein aggregation, the process by which molecules of this protein adhere to each other is strongly associated with the development of Alzheimer’s disease
Carulla’s work ultimately seeks to identify molecules that interfere with the initial stages of aggregation as a strategy to combat the disease.
Ernest Giralt is to give a public conference at the Centre de Cultura Contemporània de Barcelona on Tuesday 29 September at 19h.
In front of a non-specialized audience, he will present the innovative research being done to overcome the blood-brain barrier and to provide drug treatments for neurological diseases.
Meritxell Teixidó and Núria Bayó, researchers at IRB Barcelona, have completed the first stage of the LLAVOR (seed) Programme aimed to support innovation
The researchers recommend the experience “for 99% of scientists”
The trilingual magazine of the city of Barcelona, Barcelona Metropolis, dedicates its leading article and an extensive report to the biomedicine conducted in Barcelona. Various articles in this edition address topics related to this discipline, ranging from biomedicine as a business model and associated research fields, such as biomedical chemistry or big data, to key institutions such as the Catalan Institution for Research and Advanced Studies (ICREA).
IRB Barcelona is well represented in the magazine, with references and statements by Joan Guinovart, director of the institute, Patrick Aloy, Eduard Batlle, Natàlia Carulla, Ernest Giralt, Modesto Orozco, and Xavier Salvatella,...
Cristina Sáez, a journalist specialised in science, wrote this long article on Alzheimer’s disease, published in The Magazine of La Vanguardia. The article includes statements, among others, of various scientists specialised in this disease, including Natàlia Carulla, Ramón y Cajal associate researcher in the Peptide and Protein Laboratory, and Patrick Aloy, ICREA researcher and group leader of the Structural Bioinformatics and Network Biology Laboratory, at IRB Barcelona.
Read the article in The Magazine (in Spanish)
The European project «ECMED» (acronym of Extracellular Matrix in Epileptogenesis) is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy.
The project, which has a duration of three years and a budget of € 3.5 million, is co-funded by the European Union within the Horizon 2020 research and innovation framework program through a Marie Sklodowska-Curie grant.
Radio 5 (RNE) has broadcasted a report on a molecule developed by IRB Barcelona capable of crossing the barrier that protects the brain and transporting drugs inside. The breakthrough made by the Peptide and Protein Laboratory was recently published in Angewandte Chemie.
Roger Prades, first author of the article and who did his PhD in this lab, and Benjamí Oller, a PhD student in the same lab, explain how this shuttle works. The molecule opens the door to the development of new drugs for diseases that affect the central nervous system, in addition to giving a new opportunity to drugs previously discarded because they are unable reach the brain unaided.
Gate2Brain is one of the projects to receive research funding from the Obra Social “la Caixa”
The results of the IRB Barcelona project could have applications in various neurodegenerative diseases
Of the 221 projects presented, only 26 have been awarded funding